Skip to main content
. Author manuscript; available in PMC: 2024 May 8.
Published in final edited form as: Int J Drug Policy. 2021 Aug 3;97:103321. doi: 10.1016/j.drugpo.2021.103321

Table 1:

Descriptive and bivariate tests of differences between facilitators of access to naloxone, neighborhood sociodemographic factors and stocking buprenorphine.

Buprenorphine
Overall Yes No p-value
Buprenorphine in stock 43.81(290)
Socio-ecological factors
Community overdose rates M(SD) 16.33(6.83) 15.95(6.53) 16.33(6.83) .256
Race M(SD)
Asian 11.67(9.24) 12.11(9.49) 11.32(9.04) .112
Black, (non-Hispanic) 21.28(21.52) 18.70(20.82) 23.28(21.86) .001
Hispanic 27.31(17.96) 24.31(16.27) 29.64(28.86) <0.001
Other race 2.59(1.66) 2.53(1.53) 2.64(1.74) .823
White, (non-Hispanic) 37.14(25.84) 42.33(25.55) 33.11(25.37) <0.001
Uninsured 19.61(6.76) 17.88(6.64) 20.97(6.56) <0.001
Unmet medical needs M(SD) 10.40(2.56) 10.32(2.57) 10.46(2.54) .239
Poverty M(SD) 20.61(9.58) 18.90(9.32) 21.95(9.58) <0.001
Pharmacy-level factors
Number of private spaces 1.74(0.75) 1.94(0.63) 1.58(0.80) <0.001
Open on weekends and evenings%(n) 7.25(48) 8.97(26) 5.91(22) .133
Chain pharmacy 54.98(364) 67.59(196) 45.15(168) <0.001
Naloxone in stock 77.64(514) 80.34(233) 55.11(205) <0.001